"China's innovative drug engine" received a slap in the face

The time went back to a month ago, February 26, an ordinary Saturday
.

On this day, an article was published in the "Xinmin Evening News" that Shanghai people often read: Zhangjiang's innovative drugs ushered in an intensive harvest period
.

This article introduces a lot of good news in the field of innovative drugs in Zhangjiang in 2022 with a spring-like enthusiasm

Zhangjiang's innovative drugs usher in an intensive harvest period

The article specifically mentioned that four or five new drug R&D companies in Zhangjiang are rapidly following up the development of new crown drugs, including vaccines and specific drugs
.

Four or five new drug R&D companies in Zhangjiang are rapidly following up the research and development of new crown drugs, including vaccines and special drugs
.

On February 26, the National Health and Medical Commission announced that a total of 93 local confirmed cases of the new crown were reported nationwide, but none in Shanghai; 156 imported cases were reported, including 55 in Shanghai
.

The famous Huating Hotel in Xujiahui should have received some entry quarantine personnel at that time, but no one thought of what would happen next
.

On February 27, an asymptomatic infection appeared in Pudong; on February 28, another asymptomatic infection appeared in Jiading
.

But people were optimistic at the time
.

The gains and losses of Shanghai's epidemic prevention cannot be evaluated casually
.

But Zhangjiang, a place that bears the hope of China's innovative drugs, can talk about it

They're all grabbing food
.

They're all grabbing food
.

1.
Although China's innovative pharmaceutical companies are scattered all over the country, they are more or less connected with Zhangjiang
.

Officially, Zhangjiang has more than 1,400 innovative pharmaceutical companies
.

In addition, the scientific research capabilities here also attract pharmaceutical companies from all over the country to set up branches or cooperate

It is an understatement to say that Zhangjiang is the engine of China's innovative drugs

The most important thing is that Zhangjiang is close to Lujiazui and the Shanghai Stock Exchange.
This is the most basic element of Chinese drug "innovation"
.

The most important thing is that Zhangjiang is close to Lujiazui and the Shanghai Stock Exchange.
This is the most basic element of Chinese drug "innovation"
.

In 2020, the financing scale of Zhangjiang's biopharmaceutical industry will exceed 30 billion yuan; in the first half of 2021, the total financing will reach 26.
8 billion yuan
.

If the statistical caliber is relaxed, Zhangjiang has involved hundreds of billions of funds in the medical field in the past two years, which should not be an exaggeration

On March 17 this year, when the first batch of Pfizer's new crown special drug Paxlovid was released from Waigaoqiao to enter the customs, I wonder how Zhangjiang Pharmaceutical people felt?

(Paxlovid officially entered China)

In the face of a pandemic, there is nothing to be said for those who make medicines.
The development of vaccines and medicines is the greatest contribution to society
.

Take a closer look: Sinopharm and Kexing’s new crown vaccines, which are the most vaccinated in China, are mainly developed and produced in Beijing.

While European and American pharmaceutical companies are immersed in the research and development of specific drugs for the new crown, China's innovative drug companies are busy with involution
.

While European and American pharmaceutical companies are immersed in the research and development of specific drugs for the new crown, China's innovative drug companies are busy with involution
.

Needless to say, everyone knows that in the past two or three years, 9 PD-1s have been listed in China, and several biosimilars have been collected in the country
.

Everyone is doing popular diseases because the market is clear
.

The epidemic will always pass
.
Making anti-coronavirus drugs, apart from selling them to foreigners, won't make much money.
After all, there is no epidemic in China
.

Therefore, in Zhangjiang, Shanghai, which is the most likely land in China to produce a new crown specific drug, everyone is eagerly watching the import, distribution and use of Pfizer's drugs
.

2.
It is said that foreigners have been rushing to develop new crown drugs because the epidemic is burning their eyebrows
.

On March 23, 2021, Pfizer announced that its new crown oral drug PF-07321332 has entered Phase I clinical trials, which is the world's first new crown oral drug to enter the clinic
.

Objectively speaking, 3CL inhibitors, a potential new crown treatment drug, were researched at the first time in China.
Many papers were published in 2020, and Pfizer’s early development was noticed very early
.
There is a lot of literature on this, so you can check it out
.

But there is no Chinese company in the development
.

But there is no Chinese company in the development
.

The next thing witnessed the "research and development innovation ideas" of China's innovative pharmaceutical companies
.

On April 6, 2021, Pfizer shared the compound structure and preclinical data at the Spring Meeting of the American Chemical Society; entered Phase 2/3 clinical trials in September; obtained FDA approval for marketing at the end of December; China Food and Drug Administration approved its listing 50 days later; On March 17, 2022, the first batch of medicines will enter the country and sell for 2,300 yuan a box
.

Among the domestic companies, Simcere has the fastest hands.
At the end of November 2021, Simcere reached a cooperation with the Shanghai Institute of Materia Medica and won the candidate molecule SIM0417
.
The latest news is that on March 30, the Jiangsu Provincial Food and Drug Administration announced that the drug Simcere has been approved for clinical use
.
After the first move, and entering 2022, Asli, Junshi, Genting Xinyao, and Zhongsheng Pharmaceutical have announced the development of 3CL inhibitors
.

(Currently researching small molecule oral drugs)

Pfizer has no secrets
.
At the beginning of the outbreak in 2020, 3CL is one of the potential therapeutic drugs that has attracted worldwide attention.
Many scientists in China have studied it, and Pfizer also started to develop it in March of that year.
There must be some advantages, but how big are the advantages? Hard to say
.

Judging from the cooperation between Simcere and Shanghai Institute of Materia Medica, China's scientific research team is also capable of developing first-class drugs, and it is possible that 3CL has been on the research and development schedule of Shanghai Institute of Materia Medica
.

However, China's capital is absolutely "no devils, no strings attached"
.

However, China's capital is absolutely "no devils, no strings attached"
.

What is even more embarrassing is that China's listed companies are complacent, not developing any new drugs, but being able to process Pfizer's new crown special drugs, providing raw materials or intermediates for special drugs, and being able to obtain Pfizer's new crown drugs for third-world supply.
cargo rights
.
Some companies that have not received orders at all can make waves in the capital market as long as they announce that they have the ability to produce raw materials
.

With such a capital environment and "innovative" ideas, it is impossible not to introvert
.

Behind a new drug on the market, there must be a lot of failed research to pave the way, so there will be billions of dollars to develop a new drug
.
Even the 3CL inhibitor developed by Pfizer, a new crown specific drug, has given up halfway
.

The current "innovative environment" in the field of innovative drugs in China is generally like this: as a whole, do fast follow, and when you see someone who has a road ahead, you will be complacent.
You can overtake on a low-cost curve, or buy two varieties with money to come back, relying on China The huge population advantage grabs the market
.

Of course, China also has some excellent scientific research achievements
.
For example, in the field of new crown drugs, real biological azvudine, Junshi biological VV116, etc.
, are all varieties that have the hope of achieving greater success than Pfizer, at least we must expect so
.

The next time the National Medical Insurance Bureau really starts PD-1 collection, don't complain and complain
.
It was all doomed from the start
.

The next time the National Medical Insurance Bureau really starts PD-1 collection, don't complain and complain
.
It was all doomed from the start
.

As for some foreign-introduced varieties that have been purchased with money but have not yet been approved, it is better to dispel such opportunistic ideas as soon as possible.
China has no shortage of good vaccines
.